Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bruker - BRKR

BRKR

Close Chg Chg %
36.71 -0.55 -1.50%

Open Market

36.16

-0.55 (1.50%)

Volume: 282.63K

Last Updated:

May 1, 2026, 10:56 AM EDT

Trade Now

Company Overview: bruker - BRKR

BRKR Key Data

Open

$36.88

 Day Range

35.70 - 36.88

52 Week Range

28.53 - 56.22

 Market Cap

$5.22B

Shares Outstanding

152.22M

 Public Float

102.86M

Beta

1.20

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.15

Yield

58.33%

 Dividend

$0.05

EX-DIVIDEND DATE

Mar 23, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.91M

  

BRKR Performance

1 Week
 
 0.44%
 
1 Month
 
 -0.14%
 
3 Months
 
 -17.11%
 
1 Year
 
 -9.22%
 
5 Years
 
 -46.42%
 

BRKR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About bruker - BRKR

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

BRKR At a Glance

Bruker Corp.
40 Manning Road
Billerica, Massachusetts 01821
Phone 1-978-663-3660 Revenue 3.44B
Industry Medical Specialties Net Income -8,600,000.00
Sector Health Technology 2025 Sales Growth 2.082%
Fiscal Year-end 12 / 2026 Employees 11,085
View SEC Filings

BRKR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.081
Price to Book Ratio 2.918
Price to Cash Flow Ratio 53.33
Enterprise Value to EBITDA 17.881
Enterprise Value to Sales 2.604
Total Debt to Enterprise Value 0.228

BRKR Efficiency

Revenue/Employee 310,013.532
Income Per Employee -775.823
Receivables Turnover 4.669
Total Asset Turnover 0.57

BRKR Liquidity

Current Ratio 1.73
Quick Ratio 0.874
Cash Ratio 0.234

BRKR Profitability

Gross Margin 47.665
Operating Margin 8.154
Pretax Margin 0.64
Net Margin -0.25
Return on Assets -0.143
Return on Equity -0.406
Return on Total Capital -0.191
Return on Invested Capital -0.205

BRKR Capital Structure

Total Debt to Total Equity 83.163
Total Debt to Total Capital 45.404
Total Debt to Total Assets 32.731
Long-Term Debt to Equity 81.054
Long-Term Debt to Total Capital 44.253
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bruker - BRKR

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.53B 2.96B 3.37B 3.44B
Sales Growth
+4.67% +17.14% +13.56% +2.08%
Cost of Goods Sold (COGS) incl D&A
1.22B 1.45B 1.71B 1.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
88.80M 114.90M 183.80M 220.30M
Depreciation
51.70M 67.80M 84.70M 99.10M
Amortization of Intangibles
37.10M 47.10M 99.10M 121.20M
COGS Growth
+1.59% +18.27% +17.79% +5.47%
Gross Income
1.31B 1.52B 1.66B 1.64B
Gross Income Growth
+7.72% +16.09% +9.51% -1.39%
Gross Profit Margin
+51.63% +51.17% +49.34% +47.66%
2022 2023 2024 2025 5-year trend
SG&A Expense
843.30M 1.02B 1.27B 1.34B
Research & Development
235.90M 294.80M 376.50M 395.20M
Other SG&A
607.40M 729.40M 893.80M 946.50M
SGA Growth
+7.84% +21.45% +24.03% +5.62%
Other Operating Expense
3.80M 10.30M 11.00M 16.10M
Unusual Expense
21.50M 31.80M 138.20M 236.20M
EBIT after Unusual Expense
438.00M 450.50M 241.60M 44.00M
Non Operating Income/Expense
(8.00M) 110.10M 13.20M 38.30M
Non-Operating Interest Income
4.10M 7.50M 9.30M 14.80M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
16.10M 16.40M 47.90M 60.30M
Interest Expense Growth
+12.59% +1.86% +192.07% +25.89%
Gross Interest Expense
16.10M 16.40M 47.90M 60.30M
Interest Capitalized
- - - -
-
Pretax Income
413.90M 544.20M 206.90M 22.00M
Pretax Income Growth
+5.16% +31.48% -61.98% -89.37%
Pretax Margin
+16.36% +18.36% +6.15% +0.64%
Income Tax
116.40M 117.70M 91.40M 29.30M
Income Tax - Current - Domestic
(7.90M) 4.70M 11.00M 8.60M
Income Tax - Current - Foreign
135.30M 138.70M 144.20M 125.10M
Income Tax - Deferred - Domestic
(4.80M) (22.90M) (49.50M) (69.90M)
Income Tax - Deferred - Foreign
(6.20M) (2.80M) (14.30M) (34.50M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
298.50M 428.50M 113.80M (8.30M)
Minority Interest Expense
1.90M 1.30M 700.00K 300.00K
Net Income
296.60M 427.20M 113.10M (8.60M)
Net Income Growth
+7.04% +44.03% -73.53% -107.60%
Net Margin Growth
+11.72% +14.41% +3.36% -0.25%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
296.60M 427.20M 113.10M (8.60M)
Preferred Dividends
- - - 13.90M
-
Net Income Available to Common
296.60M 427.20M 113.10M (22.50M)
EPS (Basic)
1.996 2.918 0.7591 -0.1482
EPS (Basic) Growth
+9.06% +46.19% -73.99% -119.52%
Basic Shares Outstanding
148.60M 146.40M 149.00M 151.80M
EPS (Diluted)
1.9853 2.9022 0.7565 -0.1482
EPS (Diluted) Growth
+9.55% +46.18% -73.93% -119.59%
Diluted Shares Outstanding
149.40M 147.20M 149.50M 151.80M
EBITDA
548.30M 597.20M 563.60M 500.50M
EBITDA Growth
+5.97% +8.92% -5.63% -11.20%
EBITDA Margin
+21.67% +20.15% +16.74% +14.56%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 46.467
Number of Ratings 16 Current Quarters Estimate 0.456
FY Report Date 06 / 2026 Current Year's Estimate 2.114
Last Quarter’s Earnings 0.23 Median PE on CY Estimate N/A
Year Ago Earnings 1.83 Next Fiscal Year Estimate 2.422
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 16 16
Mean Estimate 0.46 0.57 2.11 2.42
High Estimates 0.50 0.65 2.14 2.62
Low Estimate 0.43 0.51 2.06 2.27
Coefficient of Variance 4.67 6.84 0.93 3.91

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 1 1 2
HOLD 6 6 5
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Bruker - BRKR

Date Name Shares Transaction Value
Feb 19, 2026 William Alderman Linton Director 63,243 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Thomas Bures Chief Accounting Officer 3,198 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.51 per share 116,758.98
Feb 19, 2026 Cynthia M. Friend Director 22,536 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Jack Phillips Director 4,520 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Bonnie H. Anderson Director 17,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Hermann Fritz Requardt Director 30,965 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Adelene Q. Perkins Director 29,144 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Laura A. Francis Director 9,018 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Richard A. Packer Director 93,694 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Robert J. Rosenthal Director 38,781 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Mark Robert Munch EXEC VP&PRES BRUKER NANO INC. 14,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 19, 2026 Mark Robert Munch EXEC VP&PRES BRUKER NANO INC. 128,443 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $36.94 per share 4,744,684.42
Feb 19, 2026 Mark Robert Munch EXEC VP&PRES BRUKER NANO INC. 130,443 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $22.19 per share 2,894,530.17
Feb 19, 2026 John A. Ornell Director 39,732 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Frank H. Laukien PRESIDENT & CEO; Director 38,455,167 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 1,170,190,731.81
Aug 13, 2025 Frank H. Laukien PRESIDENT & CEO; Director 38,450,510 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 1,170,049,019.30
Aug 13, 2025 Frank H. Laukien PRESIDENT & CEO; Director 38,445,672 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.78 per share 1,183,357,784.16
Aug 13, 2025 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 76,739 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.78 per share 2,362,026.42
Aug 13, 2025 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 78,159 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 2,378,378.37
Aug 13, 2025 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 79,539 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 2,420,371.77

Bruker in the News